Eagle Pharmaceuticals,Inc. (TLV:TEVA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.

Appointment of President and Chief Commercial
Officer

On December13, 2016, Eagle Pharmaceuticals,Inc., or the Company,
appointed David Pernock as President and Chief Commercial
Officer, effective upon Mr.Pernocks commencement of employment
with the Company, which is expected in January, 2017. Scott
Tarriff, who currently serves as the Companys President and Chief
Executive Officer, will resign as President of the Company,
effective upon Mr.Pernocks commencement of employment with the
Company. Mr.Tarriff will continue to serve as the Companys Chief
Executive Officer.

Mr.Pernock, age 62, is a pharmaceutical and biotechnology
industry expert. He has served as a member of the Companys Board
of Directors, or the Board, since April2015. Mr.Pernock has
served as chairman of the board of directors since September2009
and as chief executive officer since February2010 of Fibrocell
Science,Inc., a publicly-traded autologous cell and gene therapy
company. From December1993 until November2009, Mr.Pernock held
various positions at GlaxoSmithKline, or GSK, eventually serving
as senior vice president of pharmaceuticals, vaccines
(biologics), oncology, acute care, and HIV divisions. Mr.Pernock
served as president of Reliant Pharmaceuticals, or Reliant, when
Reliant was acquired by GSK. He was president of SmithKline
Beecham-Puerto Rico prior to the GSK merger. From May2009 until
February2011, Mr.Pernock served as a director of Martek
Biosciences Corporation. Mr.Pernock holds a B.S. in business
administration from Arizona State University.

Mr.Pernock does not have a family relationship with any director
or executive officer of the Company or person nominated or chosen
by the Company to become a director or executive officer, and
there are no arrangements or understandings between Mr.Pernock
and any other person to which Mr.Pernock was selected to serve as
President and Chief Commercial Officer of the Company. There have
been no transactions involving Mr.Pernock that would require
disclosure under Item 404(a)of RegulationS-Kunder the Securities
Exchange Act of 1934, as amended, or the Exchange Act.

In connection with Mr.Pernocks appointment as President and Chief
Commercial Officer, the Company and Mr.Pernock entered into an
offer letter, or the Offer Letter. to the terms of the Offer
Letter, Mr.Pernock will receive an initial annual base salary of
$515,000, subject to review and adjustment by the Company on an
annual basis. In addition, Mr.Pernock will be eligible to receive
an annual cash performance bonus. The target amount of the
performance bonus will be equal to 60% of Mr.Pernocks base
salary, with the actual bonus amount to be determined by the
Board or the Compensation Committee. Under the Offer Letter,
Mr.Pernock is entitled to severance payments in an amount equal
to Mr.Pernocks then-current monthly base salary for a period of
twelve months, plus a pro-rata portion of Mr.Pernocks annual
performance bonus for the performance period in which the
termination occurs.

to the Offer Letter, and following formal approval by the Board
or Compensation Committee, the Company will grant Mr.Pernock an
option to purchase 90,000 shares of the Companys common stock, or
the Option Grant, vesting 25% annually starting with the first
anniversary of the date of grant, subject to Mr.Pernocks
continued employment with the Company through each applicable
vesting date. Notwithstanding the foregoing, if Mr.Pernock is
terminated prior to the second anniversary of the date of grant,
without cause and not in connection with a change of control of
the Company or Mr.Pernocks voluntary departure without good
reason, one half of the shares subject to the Option Grant will
vest in full.

The foregoing description of the Offer Letter is qualified in its
entirety by reference to the Offer Letter, which is filed as
Exhibit10.1 to this Current Report on Form8-K.

Board Composition

In connection with Mr.Pernocks appointment as President and Chief
Commercial Officer, Mr.Pernock will resign from his Board
position (including his position as a member of the Boards
Nominating and Corporate Governance Committee) effective upon the
commencement of Mr.Pernocks employment with the Company, which is
expected in January, 2017.

Item7.01 Regulation FD
Disclosure.

On December19, 2016, the Company issued a press release
announcing the prospective appointment of Mr.Pernock as its
President and Chief Commercial Officer and Mr.Pernocks
resignation from his Board position (each effective upon the
commencement of Mr.Pernocks employment with the Company in
January, 2017), a copy of which is attached hereto as Exhibit99.1
and is incorporated herein by reference.

About Eagle Pharmaceuticals, Inc. (TLV:TEVA)

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules. Its central nervous system (CNS) portfolio includes Copaxone for the treatment of multiple sclerosis, Azilect for the treatment of the symptoms of Parkinson’s disease and Nuvigil for the treatment of sleep disorders, as well as several therapies for the treatment of pain care. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo in the United States and Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio outside the United States. Its women’s health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Eagle Pharmaceuticals, Inc. (TLV:TEVA) Recent Trading Information

Eagle Pharmaceuticals, Inc. (TLV:TEVA) closed its last trading session up +40.00 at 14,140.00 with 370,513 shares trading hands.